These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33823153)

  • 1. Wild-type sTREM2 blocks Aβ aggregation and neurotoxicity, but the Alzheimer's R47H mutant increases Aβ aggregation.
    Vilalta A; Zhou Y; Sevalle J; Griffin JK; Satoh K; Allendorf DH; De S; Puigdellívol M; Bruzas A; Burguillos MA; Dodd RB; Chen F; Zhang Y; Flagmeier P; Needham LM; Enomoto M; Qamar S; Henderson J; Walter J; Fraser PE; Klenerman D; Lee SF; St George-Hyslop P; Brown GC
    J Biol Chem; 2021; 296():100631. PubMed ID: 33823153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does Soluble TREM2 Protect Against Alzheimer's Disease?
    Brown GC; St George-Hyslop P
    Front Aging Neurosci; 2021; 13():834697. PubMed ID: 35153729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble TREM2 inhibits secondary nucleation of Aβ fibrillization and enhances cellular uptake of fibrillar Aβ.
    Belsare KD; Wu H; Mondal D; Bond A; Castillo E; Jin J; Jo H; Roush AE; Pilla KB; Sali A; Condello C; DeGrado WF
    Proc Natl Acad Sci U S A; 2022 Feb; 119(5):. PubMed ID: 35082148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF-α-mediated reduction in inhibitory neurotransmission precedes sporadic Alzheimer's disease pathology in young Trem2
    Ren S; Breuillaud L; Yao W; Yin T; Norris KA; Zehntner SP; D'Adamio L
    J Biol Chem; 2021; 296():100089. PubMed ID: 33434745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model.
    Zhong L; Xu Y; Zhuo R; Wang T; Wang K; Huang R; Wang D; Gao Y; Zhu Y; Sheng X; Chen K; Wang N; Zhu L; Can D; Marten Y; Shinohara M; Liu CC; Du D; Sun H; Wen L; Xu H; Bu G; Chen XF
    Nat Commun; 2019 Mar; 10(1):1365. PubMed ID: 30911003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease-associated R47H TREM2 increases, but wild-type TREM2 decreases, microglial phagocytosis of synaptosomes and neuronal loss.
    Popescu AS; Butler CA; Allendorf DH; Piers TM; Mallach A; Roewe J; Reinhardt P; Cinti A; Redaelli L; Boudesco C; Pradier L; Pocock JM; Thornton P; Brown GC
    Glia; 2023 Apr; 71(4):974-990. PubMed ID: 36480007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the minimal active soluble TREM2 sequence for modulating microglial phenotypes and amyloid pathology.
    Sheng X; Yao Y; Huang R; Xu Y; Zhu Y; Chen L; Zhang L; Wang W; Zhuo R; Can D; Chang CF; Zhang YW; Xu H; Bu G; Zhong L; Chen XF
    J Neuroinflammation; 2021 Dec; 18(1):286. PubMed ID: 34893068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triggering Receptor Expressed on Myeloid Cell 2 R47H Exacerbates Immune Response in Alzheimer's Disease Brain.
    Korvatska O; Kiianitsa K; Ratushny A; Matsushita M; Beeman N; Chien WM; Satoh JI; Dorschner MO; Keene CD; Bammler TK; Bird TD; Raskind WH
    Front Immunol; 2020; 11():559342. PubMed ID: 33101276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trem2 Splicing and Expression are Preserved in a Human Aβ-producing, Rat Knock-in Model of Trem2-R47H Alzheimer's Risk Variant.
    Tambini MD; D'Adamio L
    Sci Rep; 2020 Mar; 10(1):4122. PubMed ID: 32139718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer's disease.
    Boza-Serrano A; Ruiz R; Sanchez-Varo R; García-Revilla J; Yang Y; Jimenez-Ferrer I; Paulus A; Wennström M; Vilalta A; Allendorf D; Davila JC; Stegmayr J; Jiménez S; Roca-Ceballos MA; Navarro-Garrido V; Swanberg M; Hsieh CL; Real LM; Englund E; Linse S; Leffler H; Nilsson UJ; Brown GC; Gutierrez A; Vitorica J; Venero JL; Deierborg T
    Acta Neuropathol; 2019 Aug; 138(2):251-273. PubMed ID: 31006066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
    Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice.
    Zhao P; Xu Y; Fan X; Li L; Li X; Arase H; Tong Q; Zhang N; An Z
    MAbs; 2022; 14(1):2107971. PubMed ID: 35921534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IPSC-Derived Neuronal Cultures Carrying the Alzheimer's Disease Associated
    Martins S; Müller-Schiffmann A; Erichsen L; Bohndorf M; Wruck W; Sleegers K; Van Broeckhoven C; Korth C; Adjaye J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Untangling the Role of TREM2 in Conjugation with Microglia in Neuronal Dysfunction: A Hypothesis on a Novel Pathway in the Pathophysiology of Alzheimer's Disease.
    Basha SC; Ramaiah MJ; Kosagisharaf JR
    J Alzheimers Dis; 2023; 94(s1):S319-S333. PubMed ID: 36683512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology.
    Winfree RL; Nolan E; Dumitrescu L; Blennow K; Zetterberg H; Gifford KA; Pechman KR; Seto M; Petyuk VA; Wang Y; Schneider J; Bennett DA; Jefferson AL; Hohman TJ;
    Mol Neurodegener; 2024 May; 19(1):41. PubMed ID: 38760857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation.
    Moutinho M; Coronel I; Tsai AP; Di Prisco GV; Pennington T; Atwood BK; Puntambekar SS; Smith DC; Martinez P; Han S; Lee Y; Lasagna-Reeves CA; Lamb BT; Bissel SJ; Nho K; Landreth GE
    Genome Med; 2023 Feb; 15(1):11. PubMed ID: 36805764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer's disease.
    Claes C; Danhash EP; Hasselmann J; Chadarevian JP; Shabestari SK; England WE; Lim TE; Hidalgo JLS; Spitale RC; Davtyan H; Blurton-Jones M
    Mol Neurodegener; 2021 Jul; 16(1):50. PubMed ID: 34301296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble TREM2 ameliorates tau phosphorylation and cognitive deficits through activating transgelin-2 in Alzheimer's disease.
    Zhang X; Tang L; Yang J; Meng L; Chen J; Zhou L; Wang J; Xiong M; Zhang Z
    Nat Commun; 2023 Oct; 14(1):6670. PubMed ID: 37865646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer's disease.
    Wang ZB; Ma YH; Sun Y; Tan L; Wang HF; Yu JT;
    J Neuroinflammation; 2022 Dec; 19(1):316. PubMed ID: 36578067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.